Cargando…

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis

The emerging pathogenic yeast Candida auris is associated with antifungal resistance and high mortality. The novel antifungal agent manogepix (APX001A) inhibits glycosylphosphatidylinositol-anchored protein maturation and has demonstrated activity against numerous pathogenic fungi, including C. auri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiederhold, Nathan P., Najvar, Laura K., Shaw, Karen J., Jaramillo, Rosie, Patterson, Hoja, Olivo, Marcos, Catano, Gabriel, Patterson, Thomas F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811405/ https://www.ncbi.nlm.nih.gov/pubmed/31427304 http://dx.doi.org/10.1128/AAC.01120-19

Ejemplares similares

1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P, et al.
Publicado: (2019)

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
por: Hager, Christopher L., et al.
Publicado: (2018)

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
por: Alkhazraji, Sondus, et al.
Publicado: (2020)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
por: Larkin, Emily, et al.
Publicado: (2017)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
por: Zhao, Yanan, et al.
Publicado: (2018)

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018)

678. Galactomannan Is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial
por: Vazquez, Jose A., et al.
Publicado: (2023)

High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms
por: Ajetunmobi, Olabayo H., et al.
Publicado: (2023)

APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
por: Viriyakosol, Suganya, et al.
Publicado: (2019)

APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2017)

Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
por: Schell, Wiley A, et al.
Publicado: (2017)

1282. Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In vitro Activity Against Members of the Fusarium oxysporum and Fusarium solani Species Complexes
por: Badali, Hamid, et al.
Publicado: (2020)

1948. Rise of Candida auris Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against C. auris Causing Invasive Infections
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022)

Potency of gastrointestinal colonization and virulence of Candida auris in a murine endogenous candidiasis
por: Abe, Masahiro, et al.
Publicado: (2020)

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
por: Kapoor, Mili, et al.
Publicado: (2019)

Chitosan Ameliorates Candida auris Virulence in a Galleria mellonella Infection Model
por: Arias, Laís Salomão, et al.
Publicado: (2020)

Antifungal-Loaded Calcium Sulfate Beads as a Potential Therapeutic in Combating Candida auris
por: Butcher, Mark C., et al.
Publicado: (2022)

COVID-19-associated candidiasis and the emerging concern of Candida auris infections
por: Tsai, Chin-Shiang, et al.
Publicado: (2022)

Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
por: Sharp, Marc, et al.
Publicado: (2017)

Novel Intravenous Immunoglobulin Therapy for the Prevention and Treatment of Candida auris and Candida albicans Disseminated Candidiasis
por: Xin, Hong, et al.
Publicado: (2023)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

In Vitro Activity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.
por: Tetz, G., et al.
Publicado: (2019)

Commentary: Experimental Mouse Models of Invasive Candidiasis Caused by Candida auris and Other Medically Important Candida Species
por: Xin, Hong
Publicado: (2022)

Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis
por: Hager, Christopher, et al.
Publicado: (2017)

Absorption, Distribution, and Excretion of (14)C-APX001 after Single-Dose Administration to Rats and Monkeys
por: Mansbach, Robert, et al.
Publicado: (2017)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)

Inhibitory effects of Lactobacillus casei Shirota against both Candida auris and Candida spp. isolates that cause vulvovaginal candidiasis and are resistant to antifungals
por: Paniágua, Aline Lorenzoni, et al.
Publicado: (2021)

Is Candida auris sexual?
por: Ross, Zoe K., et al.
Publicado: (2020)

Candida auris is Coming
por: Hegde, Ashit
Publicado: (2022)

Candida and Candidiasis
por: Brandt, Mary E.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_o49glo9fm7rc82m95ut3o6cok0